Young W W, MacDonald E M, Nowinski R C, Hakomori S I
J Exp Med. 1979 Oct 1;150(4):1008-19. doi: 10.1084/jem.150.4.1008.
Two hybrid cell lines were prepared by the fusion of mouse myeloma cells with the spleen cells of BALB/c mice that had been immunized with the glycolipid ganglio-N-triosylceramide (asialo GM2). The specificity of the monoclonal antibodies produced by these hybridomas, one an IgM and the other an IgG3, has been defined by hemagglutination inhibition, complement fixation, and lysis of glycolipid liposomes by antibody and complement. A major determinant recognized by the IgM antibody is the nonreducing terminal N-acetylgalactosamine including the C6 primary hydroxyl group, but excluding the C2-acetamide group of N-acetylgalactosamine, because oxidation with galactose oxidase produced a structure showing only minimal cross-reaction with the IgM but replacement of the N-acetyl group with an N-n-butyryl group produced a glycolipid that reacts with IgM antibody to the same extent as with the unmodified glycoplipd. A major determinant recognized by the IgG3 antibody is the terminal N-acetylgalactosamine including the C2-acetamido group, but excluding the C6 primary hydroxyl group of N-acetylgalactosamine, because replacement of the N-acetyl group with an N-n-butyryl group produced a glycolipid that did not react with the IgG3 antibody; in striking contrast the IgG3 antibody reacted with the C6-oxidized glycolipid as well as with the native glycolipid. Neither antibody reacted significantly with any other natural glycolipids tested including several that are structurally related to asialo GM2 such as ganglioside GM2, ganglio-N-tetraosylceramide (asialo GM1), or ceramide dihexoside. These results indicated that in addition to the fine structure specificity described above both antibodies recognize the nonreducing terminal GalNAc beta 1 leads to 4Gal structure. The strict antigenic specificity of these monoclonal anti-glycolipid antibodies indicates their great potential as specific probes for cell surface studies.
通过将小鼠骨髓瘤细胞与用糖脂神经节苷脂 -N-三糖基神经酰胺(脱唾液酸 GM2)免疫的 BALB/c 小鼠的脾细胞融合,制备了两种杂交细胞系。这些杂交瘤产生的单克隆抗体(一种是 IgM,另一种是 IgG3)的特异性已通过血凝抑制、补体结合以及抗体和补体对糖脂脂质体的裂解来确定。IgM 抗体识别的一个主要决定簇是包括 C6 伯羟基但不包括 N-乙酰半乳糖胺的 C2-乙酰胺基的非还原末端 N-乙酰半乳糖胺,因为用半乳糖氧化酶氧化产生的结构与 IgM 仅表现出最小的交叉反应,但用 N-正丁酰基取代 N-乙酰基产生的糖脂与 IgM 抗体的反应程度与未修饰的糖脂相同。IgG3 抗体识别的一个主要决定簇是包括 C2-乙酰胺基但不包括 N-乙酰半乳糖胺的 C6 伯羟基的末端 N-乙酰半乳糖胺,因为用 N-正丁酰基取代 N-乙酰基产生的糖脂不与 IgG3 抗体反应;形成鲜明对比的是,IgG3 抗体与 C6 氧化的糖脂以及天然糖脂都反应。两种抗体与测试的任何其他天然糖脂均无明显反应,包括几种与脱唾液酸 GM2 结构相关的糖脂,如神经节苷脂 GM2、神经节苷脂 -N-四糖基神经酰胺(脱唾液酸 GM1)或神经酰胺二己糖苷。这些结果表明,除了上述精细结构特异性外,两种抗体都识别非还原末端 GalNAcβ1→4Gal 结构。这些单克隆抗糖脂抗体严格的抗原特异性表明它们作为细胞表面研究的特异性探针具有巨大潜力。